HomeComparePHMMF vs CHD

PHMMF vs CHD: Dividend Comparison 2026

PHMMF yields 0.97% · CHD yields 1.28%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PHMMF wins by $112.1K in total portfolio value
10 years
PHMMF
PHMMF
● Live price
0.97%
Share price
$96.00
Annual div
$0.93
5Y div CAGR
68.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$138.5K
Annual income
$65,086.57
Full PHMMF calculator →
CHD
CHD
● Live price
1.28%
Share price
$93.32
Annual div
$1.19
5Y div CAGR
23.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$26.4K
Annual income
$1,302.64
Full CHD calculator →

Portfolio growth — PHMMF vs CHD

📍 PHMMF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPHMMFCHD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PHMMF + CHD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
PHMMF pays
CHD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PHMMF
Annual income on $10K today (after 15% tax)
$82.26/yr
After 10yr DRIP, annual income (after tax)
$55,323.58/yr
CHD
Annual income on $10K today (after 15% tax)
$108.62/yr
After 10yr DRIP, annual income (after tax)
$1,107.24/yr
At 15% tax rate, PHMMF beats the other by $54,216.34/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PHMMF + CHD for your $10,000?

PHMMF: 50%CHD: 50%
100% CHD50/50100% PHMMF
Portfolio after 10yr
$82.5K
Annual income
$33,194.60/yr
Blended yield
40.26%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on CHD right now

PHMMF
No analyst data
Altman Z
8.3
Piotroski
6/9
CHD
Analyst Ratings
18
Buy
15
Hold
1
Sell
Consensus: Buy
Price Target
$98.40
+5.4% upside vs current
Range: $82.00 — $110.00
Altman Z
4.9
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PHMMF buys
0
CHD buys
11
PoliticianChamberTickerTypeAmountDate
Richard W. Allen🏢 House$CHD▼ Sell$15,001 - $50,0002025-10-10
Ro Khanna🏢 House$CHD▲ Buy$1,001 - $15,0002025-09-29
Lisa McClain🏢 House$CHD▼ Sell$1,001 - $15,0002025-09-25
Lisa McClain🏢 House$CHD▲ Buy$1,001 - $15,0002025-08-04
Ro Khanna🏢 House$CHD▲ Buy$1,000 - $15,0002025-08-04
Lisa McClain🏢 House$CHD▼ Sell$1,001 - $15,0002025-06-24
Lisa McClain🏢 House$CHD▲ Buy$1,001 - $15,0002025-06-17
Jonathan Jackson🏢 House$CHD▼ Sell$15,001 - $50,0002025-05-14
Jonathan Jackson🏢 House$CHD▼ Sell$1,001 - $15,0002025-05-05
Jonathan Jackson🏢 House$CHD▲ Buy$1,001 - $15,0002025-04-23
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPHMMFCHD
Forward yield0.97%1.28%
Annual dividend / share$0.93$1.19
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR68.1%23.1%
Portfolio after 10y$138.5K$26.4K
Annual income after 10y$65,086.57$1,302.64
Total dividends collected$111.9K$5.5K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: PHMMF vs CHD ($10,000, DRIP)

YearPHMMF PortfolioPHMMF Income/yrCHD PortfolioCHD Income/yrGap
1← crossover$10,863$162.67$10,857$157.30+$6.00PHMMF
2$11,901$277.61$11,814$196.49+$87.00PHMMF
3$13,212$477.81$12,887$245.97+$325.00PHMMF
4$14,970$833.33$14,097$308.68+$873.00PHMMF
5$17,501$1,483.41$15,473$388.49+$2.0KPHMMF
6$21,451$2,724.54$17,046$490.55+$4.4KPHMMF
7$28,198$5,246.31$18,861$621.76+$9.3KPHMMF
8$41,007$10,834.88$20,973$791.47+$20.0KPHMMF
9$68,632$24,753.88$23,454$1,012.51+$45.2KPHMMF
10$138,522$65,086.57$26,398$1,302.64+$112.1KPHMMF

PHMMF vs CHD: Complete Analysis 2026

PHMMFStock

Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles of marine origin for use in oncology in Spain, Italy, Germany, Ireland, rest of EU, the United States, and internationally. The company operates through three segments: Oncology, Diagnostics, and RNA interference. It develops and commercializes Yondelis for the treatment of soft tissue sarcomas and for ovarian cancer; Aplidin for treating multiple myeloma; and Zepzelca for treating patients with small cell lung cancer. The company also develops PM14 which is in phase II clinical trails for the treatment of solid tumors. In addition, it develops and markets diagnostics kits; and develops drugs with therapeutic activity based on reducing or silencing gene expression. The company was incorporated in 1986 and is based in Madrid, Spain.

Full PHMMF Calculator →

CHDConsumer Staples

Church & Dwight Co., Inc. develops, manufactures, and markets household, personal care, and specialty products. It operates through three segments: Consumer Domestic, Consumer International, and Specialty Products Division. The company offers cat litters, carpet deodorizers, laundry detergents, and baking soda, as well as other baking soda based products under the ARM & HAMMER brand; condoms, lubricants, and vibrators under the TROJAN brand; stain removers, cleaning solutions, laundry detergents, and bleach alternatives under the OXICLEAN brand; battery-operated and manual toothbrushes under the SPINBRUSH brand; home pregnancy and ovulation test kits under the FIRST RESPONSE brand; depilatories under the NAIR brand; oral analgesics under the ORAJEL brand; laundry detergents under the XTRA brand; gummy dietary supplements under the L'IL CRITTERS and VITAFUSION brands; dry shampoos under the BATISTE brand; water flossers and replacement showerheads under the WATERPIK brand; FLAWLESS products; cold shortening and relief products under the ZICAM brand; and oral care products under the THERABREATH brand. Its specialty products include animal productivity products, such as MEGALAC rumen bypass fat, a supplement that enables cows to maintain energy levels during the period of high milk production; BIO-CHLOR and FERMENTEN, which are used to reduce health issues associated with calving, as well as provides needed protein; and CELMANAX refined functional carbohydrate, a yeast-based prebiotic. The company offers sodium bicarbonate; and cleaning and deodorizing products. It sells its consumer products through supermarkets, mass merchandisers, wholesale clubs, drugstores, convenience stores, home stores, dollar and other discount stores, pet and other specialty stores, and websites and other e-commerce channels; and specialty products to industrial customers and livestock producers through distributors. The company was founded in 1846 and is headquartered in Ewing, New Jersey.

Full CHD Calculator →
📬

Get this PHMMF vs CHD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PHMMF vs SCHDPHMMF vs JEPIPHMMF vs OPHMMF vs KOPHMMF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.